

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

UNAUDITED OPERATING STATISTICS FOR THE PERIOD FROM JANUARY 1, 2023 TO JUNE 30, 2023

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the six months ended June 30, 2023, and the comparative figures as set out below.

For the period from January 1 to June 30

	2023	2022	Change
	<i>RMB'million</i>	<i>RMB'million</i>	<i>%</i>
Revenue	Approximately 220.0–230.0	118.8	Approximately 85.2–93.6

The increase in revenue was primarily attributable to the following reasons:

- (i) the commercialization of transcatheter aortic valve replacement products (including the first-generation product TaurusOne[®] and second-generation retrievable product TaurusElite[®]), has been accelerated, further increasing the Group's market share;
- (ii) the sales volume of the Group's existing neurointerventional products (including Tethys[®] Intermediate Catheter, SacSpeed[®] Balloon Dilatation Catheter, Jasper[®] Detachable Coil and Syphonet[®] Stent Retriever, etc.) has increased constantly, hence continuously contributing to the revenue growth of the Group; and
- (iii) the Group's ischemic products (including Fastunnel[®] Delivery Balloon Dilatation Catheter, etc.) whose registration applications were approved by the National Medical Products Administration of the PRC in the second quarter of 2022, have since been commercialized, contributing to the increase in the revenue of the Group.

The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2023. The above operating information is provided for investors' reference only and it shall not be taken as a measure or indication of the Group's future financial performance.

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, July 21, 2023

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei as independent non-executive Directors.